Kinlytic and Tranexamic acid

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using tranexamic acid together with urokinase may reduce the effectiveness of both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA) may reduce the therapeutic effects of both drugs due to opposing pharmacodynamic actions. Aminocaproic acid and tranexamic acid are competitive inhibitors of plasminogen activation. At high concentrations they can also directly inhibit plasmin, which is needed for the degradation of fibrin and thrombolysis. Aprotinin is a broad-spectrum protease inhibitor that inhibits plasmin. It is known to have antifibrinolytic activity and may interact with t-PAs in a similar fashion.

MANAGEMENT: No specific intervention is warranted, but clinicians should be alert to the potential for diminished therapeutic efficacy if a tissue plasminogen activator is administered to a patient who has been treated with an antifibrinolytic agent, and vice versa.

Kinlytic

Generic Name: urokinase

Brand name: Kinlytic, Abbokinase, Abbokinase Open-Cath

Synonyms: n.a.

What is Kinlytic?

Tranexamic acid

Generic Name: tranexamic acid

Brand name: Cyklokapron, Lysteda

Synonyms: Tranexamic Acid

What is Tranexamic acid?